ATHE NASDAQ
Alterity Therapeutics Limited
1W: -9.3%
1M: -26.3%
3M: -43.5%
YTD: +5.4%
1Y: -15.7%
3Y: +26.6%
5Y: -74.4%
$3.45
-0.04 (-1.15%)
Weekly Expected Move ±10.9%
$3
$3
$3
$4
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$58.4M
52W Range2.66-5.89
Volume47,139
Avg Volume37,462
Beta-0.03
Dividend—
Analyst Ratings
Company Info
CEODavid A. Stamler
Employees11
SectorHealthcare
IndustryBiotechnology
IPO Date2003-09-29
Websitealteritytherapeutics.com
500 Collins Street
Melbourne, VIC 3000
AU
Melbourne, VIC 3000
AU
61 3 9349 4906
About Alterity Therapeutics Limited
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Latest News
Catalyst Watch: Tech majors report, FOMC, Jersey Mike's IPO and more oil anxiety
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
At a glance: stocks gapping down premarket
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gozlan Lawrence Bern | A-Award | 1,000,000 | $1.00 | 2026-06-15 |
| Babarczy Julian Mich | A-Award | 2,000,000 | $1.00 | 2026-06-15 |
| Cunningham Ann Miche | 0 | — | 2026-04-17 | |
| Stamler David Allen | 0 | — | 2026-04-15 | |
| Stamler David Allen | 0 | — | 2026-04-15 |